Traws Pharma (TRAW) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to -$4.1 million.
- Traws Pharma's Income from Continuing Operations rose 5249.53% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.8 million, marking a year-over-year increase of 8884.91%. This contributed to the annual value of -$142.4 million for FY2024, which is 60141.89% down from last year.
- Traws Pharma's Income from Continuing Operations amounted to -$4.1 million in Q3 2025, which was up 5249.53% from -$1.2 million recorded in Q2 2025.
- In the past 5 years, Traws Pharma's Income from Continuing Operations registered a high of -$1.2 million during Q2 2025, and its lowest value of -$123.3 million during Q2 2024.
- Moreover, its 5-year median value for Income from Continuing Operations was -$4.6 million (2021), whereas its average is -$11.0 million.
- In the last 5 years, Traws Pharma's Income from Continuing Operations plummeted by 257566.16% in 2024 and then skyrocketed by 9898.74% in 2025.
- Quarter analysis of 5 years shows Traws Pharma's Income from Continuing Operations stood at -$3.8 million in 2021, then tumbled by 52.38% to -$5.7 million in 2022, then increased by 22.18% to -$4.5 million in 2023, then dropped by 18.29% to -$5.3 million in 2024, then grew by 23.17% to -$4.1 million in 2025.
- Its last three reported values are -$4.1 million in Q3 2025, -$1.2 million for Q2 2025, and -$5.2 million during Q1 2025.